Status: Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Participants needed: 113
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: Anagram Therapeutics, Inc.Updated: Jul 2, 2026Locations: 26
Eligibility criteria
Male and female subjects aged ≥12 years from the date of informed consent in the... [+5]
History of fibrosing colonopathy or recurring distal intestinal obstructive synd... [+3]